MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy [Yahoo! Finance]
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND